TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect
- Author
- YAMAMOTO, Yasuji1 ; SHIBATA, Jiro1 ; TERADA, Tadafumi1 ; YONEKURA, Kazuhiko1 ; SATO, Kouji1 ; HASHIMOTO, Akihiro1 ; AOYAGI, Yoshimi1 ; WIERZBA, Konstanty1 ; YANO, Shingo1 ; ASAO, Tetsuji1 ; BUZDAR, Aman U2
[1] Hanno Research Center, Taiho Pharmaceutical, Co. Ltd., Saitama, Japan
[2] The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States - Source
Clinical cancer research. 2005, Vol 11, Num 1, pp 315-322, 8 p ; ref : 46 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agoniste partiel Antagoniste Antioestrogène Récepteur hormonal Récepteur oestrogène α Récepteur oestrogène Voie orale
- Keyword (en)
- Partial agonist Antagonist Antiestrogen Hormonal receptor Estrogen receptor α Estrogen receptor Oral administration
- Keyword (es)
- Agonista parcial Antagonista Antiestrógeno Receptor hormonal Receptor estrógeno α Receptor estrógeno Vía oral
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16438772
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.315.11.1 
https://dx.doi.org/10.1158/1078-0432.315.11.1
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"315\";s:8:\"\u0000*\u0000epage\";s:3:\"322\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAMOTO\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Yasuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"SHIBATA, Jiro\";i:1;s:16:\"TERADA, Tadafumi\";i:2;s:18:\"YONEKURA, Kazuhiko\";i:3;s:11:\"SATO, Kouji\";i:4;s:18:\"HASHIMOTO, Akihiro\";i:5;s:15:\"AOYAGI, Yoshimi\";i:6;s:18:\"WIERZBA, Konstanty\";i:7;s:12:\"YANO, Shingo\";i:8;s:13:\"ASAO, Tetsuji\";i:9;s:14:\"BUZDAR, Aman U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"315\";s:8:\"\u0000*\u0000epage\";s:3:\"322\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAMOTO\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Yasuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"SHIBATA, Jiro\";i:1;s:16:\"TERADA, Tadafumi\";i:2;s:18:\"YONEKURA, Kazuhiko\";i:3;s:11:\"SATO, Kouji\";i:4;s:18:\"HASHIMOTO, Akihiro\";i:5;s:15:\"AOYAGI, Yoshimi\";i:6;s:18:\"WIERZBA, Konstanty\";i:7;s:12:\"YANO, Shingo\";i:8;s:13:\"ASAO, Tetsuji\";i:9;s:14:\"BUZDAR, Aman U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"315\";s:8:\"\u0000*\u0000epage\";s:3:\"322\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAMOTO\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Yasuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"SHIBATA, Jiro\";i:1;s:16:\"TERADA, Tadafumi\";i:2;s:18:\"YONEKURA, Kazuhiko\";i:3;s:11:\"SATO, Kouji\";i:4;s:18:\"HASHIMOTO, Akihiro\";i:5;s:15:\"AOYAGI, Yoshimi\";i:6;s:18:\"WIERZBA, Konstanty\";i:7;s:12:\"YANO, Shingo\";i:8;s:13:\"ASAO, Tetsuji\";i:9;s:14:\"BUZDAR, Aman U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"315\";s:8:\"\u0000*\u0000epage\";s:3:\"322\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAMOTO\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Yasuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"SHIBATA, Jiro\";i:1;s:16:\"TERADA, Tadafumi\";i:2;s:18:\"YONEKURA, Kazuhiko\";i:3;s:11:\"SATO, Kouji\";i:4;s:18:\"HASHIMOTO, Akihiro\";i:5;s:15:\"AOYAGI, Yoshimi\";i:6;s:18:\"WIERZBA, Konstanty\";i:7;s:12:\"YANO, Shingo\";i:8;s:13:\"ASAO, Tetsuji\";i:9;s:14:\"BUZDAR, Aman U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1158\/1078-0432.315.11.1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"315\";s:8:\"\u0000*\u0000epage\";s:3:\"322\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"YAMAMOTO\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Yasuji\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:13:\"SHIBATA, Jiro\";i:1;s:16:\"TERADA, Tadafumi\";i:2;s:18:\"YONEKURA, Kazuhiko\";i:3;s:11:\"SATO, Kouji\";i:4;s:18:\"HASHIMOTO, Akihiro\";i:5;s:15:\"AOYAGI, Yoshimi\";i:6;s:18:\"WIERZBA, Konstanty\";i:7;s:12:\"YANO, Shingo\";i:8;s:13:\"ASAO, Tetsuji\";i:9;s:14:\"BUZDAR, Aman U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:173:\"TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor \u03b1 and a partial agonist on estrogen receptor \u03b2 with low uterotrophic effect\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
